A 228839
Alternative Names: A-228839; ABT 839Latest Information Update: 24 Jan 2013
At a glance
- Originator Abbott Laboratories
- Class
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Transplant rejection
Most Recent Events
- 18 Sep 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 18 Sep 2006 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
- 23 Jun 2003 Data presented at the 4th Annual Meeting of the American Transplant Congress (ATC-2003) have been added to the Transplant Rejection therapeutic trials section